64Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: Synthesis, radiolabeling, and biologic evaluation

Journal of Nuclear Medicine

Volumn 46, Issue 7, 2005, Pages 1210-1218

  Rossin, Raffaella ^a   Pan, Dipanjan ^b   Qi, Kai ^b   Turner, Jeffrey L ^b   Sun, Xiankai ^a,c   Wooley, Karen L ^b   Welch, Michael J ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

64Cu; Enhanced permeability and retention effect; Folate nanoparticles; Folate receptor; Radiolabeling

Indexed keywords

1,4,8,11 TETRAAZACYCLOTETRADECANE TETRAACETIC ACID; ACETIC ACID DERIVATIVE; ACRYLIC ACID DERIVATIVE; COPOLYMER; COPPER 64; DRUG CARRIER; FLUORESCEIN THIOSEMICARBAZIDE; FOLATE RECEPTOR; FOLIC ACID; NANOPARTICLE; POLYACRYLIC ACID B METHYLACRYLATE; THIOSEMICARBAZIDE DERIVATIVE; UNCLASSIFIED DRUG; COPPER; CROSS LINKING REAGENT; DIAGNOSTIC AGENT; NANOTUBE; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CROSS LINKING; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG LIVER LEVEL; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MICELLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; SQUAMOUS CELL CARCINOMA; TUMOR VASCULARIZATION; TUMOR VOLUME; XENOGRAFT; ANIMAL; ANTIBODY SPECIFICITY; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; NASOPHARYNX TUMOR; NUDE MOUSE; SCINTISCANNING; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; COPPER RADIOISOTOPES; CROSS-LINKING REAGENTS; DRUG DELIVERY SYSTEMS; FEMALE; FOLIC ACID; HUMANS; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; NANOTUBES; NASOPHARYNGEAL NEOPLASMS; ORGAN SPECIFICITY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 23844533668     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001;53:283-318.
2. Guccione S, Li KCP, Bednarski MD. Vascular-targeted nanoparticles for molecular imaging and therapy. Methods Enzymol. 2004;386:219-236.
3. Storm G, Belliot SO, Daemen T, Lasic DD. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev. 1995;17:31-48.
4. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2002;54:631-651.
5. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2004;56:1649-1659.
6. Munn LL. Aberrant vascular architecture in tumors and its importance in drug-based therapies. Drug Discov Today. 2003;8:396-403.
7. Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA. 1998;95:4607-4612.
8. Padera TP, Kadambi A, di Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science. 2002;296:1883-1886.
9. Hood JD, Bednarski M, Frausto R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science. 2002;296:2404-2407.
10. 3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res. 2003;63:5838-5843.
11. Dubey PK, Mishra V, Jain S, Mahor S, Vyas SP. Liposomes modified with cyclic RGD peptide for tumor targeting. J Drug Target. 2004;12:257-264.
12. 90Y- labeled nanoparticles. Int J Radiat Oncol Biol Phys. 2004;58:1215-1227.
13. 3 receptor-ligand interactions. Macromolecules. 2004;37:7109-7115.
14. Thomas TP, Patri AK, Myc A, et al. In vitro targeting of synthesized antibody-conjugated dendrimer nanoparticles. Biomacromolecules. 2004;5:2269-2274.
15. Farokhzad OC, Jon S, Khademhosseini A, Tran T-NT, LaVan DA, Langer R. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 2004;64:7668-7672.
16. Stella B, Arpicco S, Peracchia MT, et al. Design of folic acid-conjugated nanoparticles for drug targeting. J Pharm Sci. 2000;89:1452-1464.
17. Pan D, Turner JL, Wooley KL. Folic acid-conjugated nanostructured materials designed for cancer cell targeting. Chem Commun (Camb). 2003;7:2400-2401.
18. Pan XQ, Wang H, Lee RJ. Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model. Pharm Res. 2003:20:417-422.
19. Oyewumi MO, Yokel RA, Jay M, Coakley T, Mumper RJ. Comparison of cell uptake, biodistribution and tumor retention of folate coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice. J Control Release 2004;95:613-626.
20. Choi H, Choi SR, Zhou R, Kung HF, Chen I-W. Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Acad Radiol. 2004;11:996-1004.
21. Hattori Y, Maitani Y. Enhanced in vitio DNA transfection efficiency by novel folate-linked nanoparticles in human prostate cancer and oral cancer. J Control Release. 2004;97:173-183.
22. Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S. Tumor cell targeting of liposome-entrapped drugs with phospholipid anchored folic acid-PEG conjugates. Adv Drug Del Rev. 2004;56:1177-1192.
23. Antony AC. Folate receptors. Annu Rev Nutr. 1996;16:501-521.
24. Garin-Chesa P, Campbell I, Saigo PE, Lewis JLJ, Old LJ, Rettig WJ. Trophoblast and ovarian cancer antigen LK26: sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol. 1993;142:557-567.
25. Leamon CP, Reddy JA. Folate-targeted chemotherapy. Adv Drug Del Rev. 2004;56:1127-1141.
26. Ke C-Y, Mathias CJ, Green MA. The folate receptor as a molecular target for tumor-selective radionuclide delivery. Nucl Med Biol. 2003;30:811-817.
27. Wooley KL. Shell cross-linked polymer assemblies nanoscale constructs inspired from biological systems. J Polym Sci [A1]. 2000;38:1397-1407.
28. Becker ML, Remsen EE, Pan D, Wooley KL. Peptide- derivatized shell-cross-linked nanoparticles. 1. Synthesis and characterization. Bioconjug Chem. 2004;15:699-709.
29. Sun X, Anderson CJ. Production and applications of copper-64 radiopharmaceuticals. Methods Enzymol. 2004;386:237-261.
30. 64Cu using a biomedical cyclotron. Nucl Med Biol. 1997;24:35-43.
31. Mathias CJ, Wang S, Lei RJ, Waters DJ, Low PS, Green MA. Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate. J Nucl Med. 1996;37:1003-1008.
32. Qi K, Ma Q, Remsen EE, Clark CGJ, Wooley KL. Determination of the bioavailability of biotin conjugated onto shell cross-linked (SCK) nanoparticles. J Am Chem Soc. 2004;126:6599-6607.
33. Lewis MR, Kao JY, Anderson AL, Shively JE, Raubitschek A. An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA. Bioconjug Chem. 2001;12:320-324.
34. Mc Hugh M, Cheng YC. Demonstration of a high affinity folate binder in human cell membranes and its characterization in cultured human KB cells. J Biol Chem. 1979;254:11312-11318.
35. Reddy JA, Abburi C, Hofland H, et al. Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors. Gene Ther. 2002;9:1542-1550.
36. Pan XQ, Wang H, Lee RJ. Boron delivery to a murine lung carcinoma using folate receptor-targeted liposomes. Anticancer Res. 2002;22:1629-1634.
37. Leamon CP, Cooper SP, Hardee GE. Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo. Bioconjug Chem. 2003;14:738-747.
38. Gabizon A, Horowitz AT, Goren D, Tzemach D, Shmeeda H, Zalipsky S. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin Cancer Res. 2003;9:6551-6559.
39. Pauwels EKJ, Ribeiro MJ, Stoot JHMB, McCready VR, Bourguignon M, Maziere B. FDG accumulation and tumor biology. Nucl Med Biol. 1998;25:317-322.